cholic acid
Commercial- Indications
- Cerebrotendinous xanthomatosis, Primary bile acid synthesis disorders, Neonatal cholestasis
Company intelligence / Profile preview
Laboratoires CTRS specializes in the development and commercialization of therapies for rare and ultra‐rare diseases. Its lead product, Orphacol® (cholic acid), treats patients with specific genetic defects affecting bile acid synthesis. The company has established international partnerships to ensure access to its products and has completed clinical studies on pediatric formulations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Laboratoires CTRS.